ANXA1 and breast cancer: It has been reported that rosiglitazone and prostaglandin J2, both PPARγ ligands, increase AnxA1 expression, but such has been demonstrated in MDA-MB-231 and MCF-7 breast cancer cells to variable results and not at inflammatory conditions (Chen et al., 2017).